Sandoz launches its Aloxi generic
Sandoz has introduced its Aloxi generic (palonosetron hydrochloride injection). The drug is indicated to help prevent nausea and vomiting associated with chemotherapy in adults and children ages one month old to less than 17 years old.
"Chemotherapy-induced nausea and vomiting can often add unnecessary hardship to cancer treatment - exacerbating an already sensitive and emotional time for cancer patients," Sandoz president Carol Lynch said. "That is why it is important for Sandoz to provide patients with a high-quality and accessible generic version of this medicine in the United States."
Sandoz's Aloxi generic will be marketed in single-dose vials in 0.25 mg/ml dosage strength. The product had U.S. sales of roughly $447 million for the 12 months ended January 2018, according to IQVIA data.
"Chemotherapy-induced nausea and vomiting can often add unnecessary hardship to cancer treatment - exacerbating an already sensitive and emotional time for cancer patients," Sandoz president Carol Lynch said. "That is why it is important for Sandoz to provide patients with a high-quality and accessible generic version of this medicine in the United States."
Sandoz's Aloxi generic will be marketed in single-dose vials in 0.25 mg/ml dosage strength. The product had U.S. sales of roughly $447 million for the 12 months ended January 2018, according to IQVIA data.